Author: Tao, Kaiming; Tzou, Philip L.; Nouhin, Janin; Bonilla, Hector; Jagannathan, Prasanna; Shafer, Robert W.
Title: SARS-CoV-2 Antiviral Therapy Cord-id: fi993f4n Document date: 2021_7_28
ID: fi993f4n
Snippet: The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antiviral therapies for COVID-19, including research spanning preclinical and clinical drug development efforts, with an emphasis on antiviral compounds that are in clinical development or that are high priorities for clinical development. The review is divided into
Document: The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antiviral therapies for COVID-19, including research spanning preclinical and clinical drug development efforts, with an emphasis on antiviral compounds that are in clinical development or that are high priorities for clinical development. The review is divided into sections on compounds that inhibit SARS-CoV-2 enzymes, including its polymerase and proteases; compounds that inhibit virus entry, including monoclonal antibodies; interferons; and repurposed drugs that inhibit host processes required for SARS-CoV-2 replication. The review concludes with a summary of the lessons to be learned from SARS-CoV-2 drug development efforts and the challenges to continued progress.
Search related documents:
Co phrase search for related documents- accessory protein and action mechanism: 1
- accessory protein and active site: 1, 2
- accessory protein and acute ards respiratory distress syndrome: 1
- accessory protein and acute infection: 1, 2, 3, 4, 5, 6
- action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- active inhibitor and acute infection: 1
- active metabolite and acute ards respiratory distress syndrome: 1, 2, 3
- active metabolite and acute infection: 1
- active site and acute ards respiratory distress syndrome: 1, 2
- active site and acute infection: 1, 2, 3, 4, 5, 6
- active site cysteine and acute infection: 1
- active triphosphate form and acute infection: 1
- activity broad spectrum and acute ards respiratory distress syndrome: 1, 2, 3
- activity broad spectrum and acute infection: 1, 2, 3, 4
- activity exert and acute ards respiratory distress syndrome: 1, 2
- activity exert and acute infection: 1
- activity mechanism and acute ards respiratory distress syndrome: 1
Co phrase search for related documents, hyperlinks ordered by date